NasdaqGS - Nasdaq Real Time Price USD

Cytokinetics, Incorporated (CYTK)

65.18 -1.64 (-2.45%)
As of 11:21 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
7,530.00
7,530.00
94,588.00
70,428.00
55,828.00
Cost of Revenue
330,123.00
330,123.00
240,813.00
159,938.00
96,951.00
Gross Profit
-322,593.00
-322,593.00
-146,225.00
-89,510.00
-41,123.00
Operating Expense
173,612.00
173,612.00
177,977.00
96,803.00
52,820.00
Operating Income
-496,205.00
-496,205.00
-324,202.00
-186,313.00
-93,943.00
Net Non Operating Interest Income Expense
-30,039.00
-30,039.00
-39,814.00
-29,001.00
-33,347.00
Other Income Expense
--
--
-24,939.00
--
--
Pretax Income
-526,244.00
-526,244.00
-388,955.00
-215,314.00
-127,290.00
Net Income Common Stockholders
-526,244.00
-526,244.00
-388,955.00
-215,314.00
-127,290.00
Diluted NI Available to Com Stockholders
-526,244.00
-526,244.00
-388,955.00
-215,314.00
-127,290.00
Basic EPS
-5.45
-5.45
-4.33
-2.80
-1.97
Diluted EPS
-5.45
-5.45
-4.33
-2.80
-1.97
Basic Average Shares
96,524.00
96,524.00
89,825.00
76,886.00
64,524.00
Diluted Average Shares
96,524.00
96,524.00
89,825.00
76,886.00
64,524.00
Total Operating Income as Reported
-496,205.00
-496,205.00
-324,202.00
-186,313.00
-93,943.00
Total Expenses
503,735.00
503,735.00
418,790.00
256,741.00
149,771.00
Net Income from Continuing & Discontinued Operation
-526,244.00
-526,244.00
-388,955.00
-215,314.00
-127,290.00
Normalized Income
-526,244.00
-526,244.00
-364,016.00
-215,314.00
-127,290.00
Interest Income
27,629.00
27,629.00
11,342.00
331.00
5,329.00
Interest Expense
57,668.00
57,668.00
51,156.00
29,332.00
38,676.00
Net Interest Income
-30,039.00
-30,039.00
-39,814.00
-29,001.00
-33,347.00
EBIT
-468,576.00
-468,576.00
-337,799.00
-185,982.00
-88,614.00
EBITDA
-456,684.00
-456,684.00
-331,985.00
-183,706.00
-86,783.00
Reconciled Cost of Revenue
330,123.00
330,123.00
240,813.00
159,938.00
96,951.00
Reconciled Depreciation
11,892.00
11,892.00
5,814.00
2,276.00
1,831.00
Net Income from Continuing Operation Net Minority Interest
-526,244.00
-526,244.00
-388,955.00
-215,314.00
-127,290.00
Total Unusual Items Excluding Goodwill
--
--
-24,939.00
--
--
Total Unusual Items
--
--
-24,939.00
--
--
Normalized EBITDA
-456,684.00
-456,684.00
-307,046.00
-183,706.00
-86,783.00
12/31/2020 - 4/30/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BBIO BridgeBio Pharma, Inc.
23.87
-4.64%
 
DAWN Day One Biopharmaceuticals, Inc.
13.45
-11.49%
 
IMVT Immunovant, Inc.
27.62
-4.10%
 
MDGL Madrigal Pharmaceuticals, Inc.
192.12
-6.13%
 
BPMC Blueprint Medicines Corporation
89.08
-3.45%
 
CLRB Cellectar Biosciences, Inc.
3.0300
-0.98%
 
JANX Janux Therapeutics, Inc.
46.79
-2.95%
 
BHVN Biohaven Ltd.
38.17
-1.41%
 
CRNX Crinetics Pharmaceuticals, Inc.
41.48
-4.25%
 
APLS Apellis Pharmaceuticals, Inc.
47.74
-4.39%